Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients
NCT06909942
Summary
Patients will be informed by obtaining consent when they meet the inclusion criteria. Written consent will be obtained when the patient arrives in the operating room. The patient's characteristics (gender, age, liver disease) and the biochemistry, hemogram and coagulation values taken before the surgery will be written on the prepared follow-up form. After the hand grip strength is recorded in kg with a mechanical thenar muscle dynamometer, the SARC-F test questionnaire consisting of five questions will be administered to the patient and the SARC-F score will be calculated and recorded. Routine monitoring (ECG, pulse oximetry, non-invasive blood pressure cuff, TOF monitoring, BIS monitoring) will be performed for the liver transplant recipient. The routine anesthesia induction protocol will be applied to the patient for liver transplant recipients (thiopental (5-7 mg/kg), fentanyl (1-2 mcg/kg) and rocuronium (1mg /kg)), the time after rocuronium will be recorded and the reset time of the TOF device will be determined. After intubation, the intubation score will be recorded on the follow-up form as a value between 5 and 20. During the case, the times when the TOF value exceeds 30% and the times when diaphragm activity is detected at -3 cmH2O on mechanical ventilation will be recorded, 0.1 mg/kg rocuronium will be added as required for routine anesthesia follow-up. The phase of the transplant operation (Dissection-Anhepatic-Neohepatic) in which the added rocuronium is added will be specified. The transfusion content and amounts within the case will be recorded on the follow-up form. The extubation times in hours, the transfer time to the ward, the discharge time from the hospital and the need for reintubation of patients who are routinely transferred to the intensive care unit in an intubated state at the end of the case will be recorded.
Eligibility
Inclusion Criteria: * Patients with American Society of Anesthesiologists (ASA) 2-3, * Patients over the age of 18, * Liver transplant recipient candidates who have agreed to receive an organ transplant Exclusion Criteria: * Patients who are unconscious enough to not be included in the study (patients for whom consent cannot be obtained and the study cannot be explained) * Patients under the age of 18 * Patients aged 65 and over * Patients with advanced renal failure * Patients with massive ascites in the abdomen * Patients with advanced heart failure or high pulmonary artery pressure for whom routine anesthesia induction protocols must be excluded * Patients with psychosis or substance abuse Patients with a known adverse reaction to rocuronium
Conditions4
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06909942